Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian Markets Witness Bloody Monday
Mon, 9 Mar Closing

Indian markets witnessed a sell-off as BSE Sensex and NSE-Nifty tanked over 2%. The markets opened today's session on a weak note following global cues. U.S employment figures indicated towards the fact that the Federal Reserve might consider raising interest rates sooner. Amidst speculation coupled with worries over the Greek crisis and Asian economic numbers, Asian stock markets predominantly traded in the red. European stocks are also trading the red following these concerns. DAX and FTSE are trading with 0.4% and 0.7% losses.

BSE Sensex and NSE Nifty fell 604 points and 181 points respectively. Banks, Capital Goods and IT sector were the major losers. However, the pharmaceutical sector was buoyant against the sell off and managed to close in the green. BSE Mid Cap and BSE Small Cap, which fell over 1%, however bettered the broader indices. Crude oil prices have fallen 0.8% and are currently trading at Rs 3,113 per barrel. Gold prices and silver prices have increased 0.5% and 0.4%, respectively. Gold prices, per 10 grams, is trading at Rs 26,100 while Silver prices, per kilogram, is trading at Rs 36,150. The price of Indian Rupee against the U.S. Dollar increased 0.7% to Rs 62.59.

Despite the power sector, as a whole, remained in the red, companies such as Jindal steel and Power and Suzlon traded in the green. During early trade the stock price of Suzlon gained over 4.5%, however, ended the day with 2% gains. The debt-ridden company plans to off-load the debt by selling its forging and foundry arm. The company has invested about Rs 10 bn in the arm. The forging arm of the company is located at Baroda while foundry arm in Coimbatore. The company has been making attempts to get itself out of the debt. It may be noted that on January 22, Suzlon sold its 100% ownership in Senvion for Rs 72 bn while secured investment of about Rs 18 billion from Dilip Sanghvi Family and Associates (DSA).

The Ranbaxy and Sun Pharma deal got another boost when Punjab and Haryana high court gave a green light to the "Scheme of Agreement" between the two companies. Following such developments both the companies hit their respective all-time highs. While Ranbaxy gained over 2.4%, Sun Pharma gained over 1%. In may be noted that recently, Sun Pharma had acquired approvals of various patents.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Markets Witness Bloody Monday". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.